Sevion is overcoming the constraints of conventional antibody discovery approaches by applying an integrated suite of technologies that unlocks previously inaccessible targets, enabling entirely new therapeutic classes to be discovered. Sevion is applying this technology to develop both a proprietary product pipeline, and to assist drug development partners in discovering new and novel therapeutic candidates.
Target Opportunity: Multispanning membrane proteins, particularly GPCRs and ion channels, represent major classes of cell surface therapeutic targets involved in nearly every therapeutic area, and are the targets of >50% of all therapeutics.
Cow Antibody Scaffold Accesses Difficult Therapeutic Targets: Despite the enormous diversity of the antibody repertoire, human antibodies all have a similar geometry, shape and binding mode. Sevion scientists have discovered and humanized a novel class of therapeutic antibodies derived from cows that have a highly unusual structure for binding targets.
Spatially Addressed Antibody Libraries: Traditional antibody drug discovery methods (phage/yeast display or immunization) rely on competitive selection from a pool of antibodies to identify a lead therapeutic candidate. While this approach has led to many successful antibody therapeutics, targets have been limited to proteins which can be easily purified.
Sevion’s Chimerasome technology is based on a single protein that can be assembled to form a spherical protein nanocage encapsulating drugs or nucleic acid therapeutics.